文献速递贫血与红细胞疾病

母体铁调素决定小鼠胚胎铁稳态

Maternal hepcidin determines embryo iron homeostasis in mice.
PubMed 文献 · Blood · 2020-01-01

研究通过构建有无铁调素的母体与胚胎组合,发现健康妊娠中母体而非胚胎铁调素决定胚胎与胎盘铁储备;炎症可抵消妊娠依赖的母体铁调素抑制;给孕鼠使用铁调素肽模拟物模拟不同活性水平,高剂量导致母体铁限制和贫血、胎盘和胚胎重量降低、胚胎贫血及死亡率增加,低剂量虽不引起母体贫血但仍导致胚胎贫血、组织铁缺乏(包括脑)和体重降低。

要点

  • 健康妊娠中母体铁调素而非胚胎铁调素决定胚胎和胎盘铁储备。
  • 炎症可抵消妊娠依赖的母体铁调素抑制。
  • 铁调素激动剂低剂量不引起母体贫血但仍对胚胎产生不良影响。

核心结论

  • 妊娠期间母体铁调素抑制对母体和胚胎铁稳态及健康至关重要。

研究设计与样本

  • 研究在铁充足或铁过载小鼠中生成有或无铁调素的母体与胚胎组合。
  • 通过给孕鼠施用铁调素肽模拟物模拟母体铁调素活性范围。

主要发现

  • 健康妊娠中母体而非胚胎铁调素决定胚胎和胎盘铁储备。
  • 炎症可抵消妊娠依赖的母体铁调素抑制。
  • 较高剂量铁调素激动剂导致母体铁限制和贫血、胎盘和胚胎重量降低、胚胎贫血及胚胎死亡率增加。
  • 低剂量激动剂不引起母体贫血但仍导致胚胎贫血、组织铁缺乏(包括脑)和体重降低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron disorders are associated with adverse pregnancy outcomes, yet iron homeostatic mechanisms during pregnancy are poorly understood. In humans and rodents, the iron-regulatory hormone hepcidin is profoundly decreased in pregnant mothers, which is thought to ensure adequate iron availability for transfer across placenta. However, the fetal liver also produces hepcidin, which may regulate fetal iron endowment by controlling placental iron export. To determine the relative contribution of maternal vs embryo hepcidin to the control of embryo iron endowment in iron-sufficient or iron-overloaded mice, we generated combinations of mothers and embryos that had or lacked hepcidin. We found that maternal, but not embryonic, hepcidin determined embryo and placental iron endowment in a healthy pregnancy. We further determined that inflammation can counteract pregnancy-dependent suppression of maternal hepcidin. To establish how essential maternal hepcidin suppression is for embryo iron homeostasis, we mimicked the range of maternal hepcidin activity by administering a hepcidin peptide mimetic to pregnant mice. This also allowed us to determine the effect of isolated maternal hepcidin excess on pregnancy, in the absence of other confounding effects of inflammation. Higher doses of hepcidin agonist caused maternal iron restriction and anemia, lower placenta and embryo weight, embryo anemia, and increased embryo mortality. Low agonist doses did not cause maternal anemia but still adversely affected the embryo, causing anemia, tissue iron deficiency (including in the brain), and decreased weight. Our studies demonstrate that suppression of maternal hepcidin during pregnancy is essential for maternal and embryo iron homeostasis and health.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sangkhae V, Fisher AL, Chua KJ, et al. Maternal hepcidin determines embryo iron homeostasis in mice. Blood. 2020. PMID: 32584957. doi:10.1182/blood.2020005745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。